Breyanzi

FDA Approves New Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma Bookmark

The U.S. Food and Drug Administration (FDA) has approved a cell-based gene therapy known as lisocabtagene maraleucel (brand name Breyanzi) for relapsed or refractory large B-cell lymphoma.

.